Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
June 27 2023 - 1:00AM
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage
biotech company developing a new class of custom-built protein
drugs known as DARPin therapeutics, has announced it will present
on its Radio DARPin Therapy (RDT) Platform at the 2023 Society
of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
being held from June 24-27 in Chicago, Illinois.
The presentation details are as follows:
Title: DARPin platform for the development of
powerful targeting agents for radioligand therapySession
Title: Innovative Radiopharmaceutical Development for
Targeted Cancer TherapySession Number:
SS39Session Location & Timing: Room S504ab;
June 27, 2023; 9:30–10:45 am local timeOrder in
Session: 6Presentation Time: 10:15–10:35
am local time
Access to the slides presented at SNMMI will be available on the
company website, www.molecularpartners.com under the "Scientific
Documents” tab.
Molecular Partners’ RDT platform represents a unique and
innovative approach for the delivery of radioactive payloads to
solid tumors. Thanks to their small size and their high specificity
and affinity, DARPins represent ideal vectors for efficient
delivery of therapeutic radionuclides: RDT has the potential to
selectively deliver radionuclides deeply into the targeted tumor,
with long tumor retention, causing direct tumor cell killing, while
limiting systemic side effects.
Molecular Partners is developing a portfolio of RDTs, both
proprietary as well as in collaboration with external partners. The
tumor-associated protein Delta-like ligand 3 (DLL3) is the first
disclosed target of Molecular Partner’s proprietary RDT
candidates.
Preclinical data shows that RDT can deliver high amount of
radioactivity to tumors without accumulating in healthy tissues.
Molecular Partners has also demonstrated that through DARPin
engineering it can reduce the uptake of DARPin radio conjugates in
the kidneys and therefore reduce kidney damage, a key limitation of
protein-based radio therapies.
Authors & Affiliations: Christian Lizak,1
Andreas Bosshart,1 Stephan Wullschleger,1 Martin Behe,2 Alain
Blanc,2 Stefan Imobersteg,2 Alexandra Neculcea,1 Jacqueline
Blunschi,1 Liridon Abduli,1 Sarah Schütz,1 Julia Wolter, 1
Christian Reichen,1 Amelie Croset,1 Alessandra Villa,1 Anne
Goubier,1 Philippe Legenne,1 Roger Schibli,2 and Daniel Steiner1
1Molecular Partners AG, Schlieren-Zurich, Switzerland; 2Paul
Scherrer Institute, Villingen, Switzerland
About Molecular Partners AGMolecular Partners
AG is a clinical-stage biotech company developing DARPin (designed
ankyrin repeat protein) therapeutics, a new class of custom-built
protein drugs designed to address challenges current modalities
cannot. The Company has formed partnerships with leading
pharmaceutical companies to advance DARPin therapeutics in the
areas of oncology and virology and has compounds in various stages
of clinical and preclinical development across multiple therapeutic
areas. www.molecularpartners.com; Find us on Twitter -
@MolecularPrtnrs
Cautionary Note Regarding Forward-Looking
Statements Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, implied and express statements regarding the
clinical development of Molecular Partners’ current or future
product candidates, expectations regarding timing for reporting
data from ongoing clinical trials or the initiation of future
clinical trials, the potential therapeutic and clinical benefits of
Molecular Partners’ product candidates, the selection and
development of future antiviral or other programs, and Molecular
Partners’ expected expenses and cash utilization for 2023 and its
expectation that its current cash resources will be sufficient to
fund its operations and capital expenditure requirements into 2026.
These statements may be identified by words such as “believe”,
“expect”, “may”, “plan”, “potential”, “will”, “would” and similar
expressions, and are based on Molecular Partners AG’s current
beliefs and expectations. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Some of the key factors
that could cause actual results to differ from Molecular Partners’
expectations include its plans to develop and potentially
commercialize its product candidates; Molecular Partners’ reliance
on third party partners and collaborators over which it may not
always have full control; Molecular Partners’ ongoing and planned
clinical trials and preclinical studies for its product candidates,
including the timing of such trials and studies; the risk that the
results of preclinical studies and clinical trials may not be
predictive of future results in connection with future clinical
trials; the timing of and Molecular Partners’ ability to obtain and
maintain regulatory approvals for its product candidates; the
extent of clinical trials potentially required for Molecular
Partners’ product candidates; the clinical utility and ability to
achieve market acceptance of Molecular Partners’ product
candidates; clinical trials or operations, or the operations of
third parties on which it relies; Molecular Partners’ plans and
development of any new indications for its product candidates;
Molecular Partners’ commercialization, marketing and manufacturing
capabilities and strategy; Molecular Partners’ intellectual
property position; Molecular Partners’ ability to identify and
in-license additional product candidates; and other risks and
uncertainties that are described in the Risk Factors section of
Molecular Partners’ Annual Report on Form 20-F for the fiscal year
ended December 31, 2022 filed with Securities and Exchange
Commission (SEC) on March 9, 2023 and other filings Molecular
Partners makes with the SEC. These documents are available on the
Investors page of Molecular Partners’ website at
www.molecularpartners.com. Any forward-looking statements speak
only as of the date of this press release and are based on
information available to Molecular Partners as of the date of this
release, and Molecular Partners assumes no obligation to, and does
not intend to, update any forward-looking statements, whether as a
result of new information, future events or otherwise.
For further details, please contact:Seth Lewis,
Investor Relationsseth.lewis@molecularpartners.comTel: +1 781 420
2361
Antonio Ligi, CommunicationsZürich-Schlieren,
Switzerlandantonio.ligi@molecularpartners.comTel: +41 79 723 36
81
Molecular Partners (NASDAQ:MOLN)
Historical Stock Chart
From Oct 2024 to Oct 2024
Molecular Partners (NASDAQ:MOLN)
Historical Stock Chart
From Oct 2023 to Oct 2024